期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Glycobiology in osteoclast differentiation and function
1
作者 shufa yang Ziyi He +2 位作者 Tuo Wu Shunlei Wang Hui Dai 《Bone Research》 SCIE CAS CSCD 2023年第4期651-664,共14页
Glycans,either alone or in complex with glycan-binding proteins,are essential structures that can regulate cell biology by mediating protein stability or receptor dimerization under physiological and pathological cond... Glycans,either alone or in complex with glycan-binding proteins,are essential structures that can regulate cell biology by mediating protein stability or receptor dimerization under physiological and pathological conditions.Certain glycans are ligands for lectins,which are carbohydrate-specific receptors.Bone is a complex tissue that provides mechanical support for muscles and joints,and the regulation of bone mass in mammals is governed by complex interplay between bone-forming cells,called osteoblasts,and bone-resorbing cells,called osteoclasts.Bone erosion occurs when bone resorption notably exceeds bone formation.Osteoclasts may be activated during cancer,leading to a range of symptoms,including bone pain,fracture,and spinal cord compression.Our understanding of the role of protein glycosylation in cells and tissues involved in osteoclastogenesis suggests that glycosylation-based treatments can be used in the management of diseases.The aims of this review are to clarify the process of bone resorption and investigate the signaling pathways mediated by glycosylation and their roles in osteoclast biology.Moreover,we aim to outline how the lessons learned about these approaches are paving the way for future glycobiology-focused therapeutics. 展开更多
关键词 OSTEOCLAST ALONE FUNCTION
下载PDF
Jinlong capsule decreases adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma
2
作者 Wukui Huang Dengyao Liu +6 位作者 Lina You shufa yang Mo Liu Peng Gu Pingju Wang Baikere Pahaerding Xiwen Fan 《The Chinese-German Journal of Clinical Oncology》 CAS 2015年第2期87-91,共5页
Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-tw... Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-two patients with hepatocellular carcinoma were randomly divided into the control group and experimental group. On the first day after TACE, the experimental group started receiving four Jinlong capsules orally three times daily, whereas the control group did not receive the treatment.Results The incidences of erythropenia and thrombocytopenia in the experimental group was lower than those in the control group(P = 0.040 and 0.033, respectively). The differences in serum levels of aminotransferase, albumin, potassium, and sodium between the two groups were significant(P = 0.034, 0.034, 0.013, and 0.044, respectively). The mean durations of stomachache and abdominal distension in the experimental group was significantly shorter than those in the control group(P = 0.004 and 0.021, respectively). However, there were no significant differences in the incidences of nausea, fever, and vomiting between the two groups(P = 0.490, 0.495, and 0.585, respectively). Conclusion The reduction in the incidence rate and duration of partial adverse reactions after TACE was observed in hepatocellular carcinoma patients treated with Jinlong capsule compared to untreated patients, suggesting possible beneficial effects exerted by Jinlong capsule on the reduction of TACE-induced liver damage, thereby improving liver function and, consequently, the quality of life. 展开更多
关键词 Jinlong capsule primary hepatocellular carcinoma (PHC) transcatheter artedal chemoembolization (TACE) adverse reaction
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部